Fosnetupitant

Fosnetupitant is a medication used for the treatment of chemotherapy-induced [nausea and vomiting]. It is a prodrug of netupitant. It is used in combination with palonosetron hydrochloride and formulated as the salt fosnetupitant chloride hydrochloride for intravenous use.
In 2018, the US Food and [Drug Administration] approved the intravenous formulation of a fixed [dose combination] of fosnetupitant and palonosetron. The combination is also approved for medical use in the European Union, and in Canada.